Hepatitis B and C viruses determine chronic infections of the liver in about 600 million people worldwide, and foster hepatic injuries such as steatosis and fibrosis that can lead to cirrhosis and hepatocarcinoma (HCC). The team's main aims consist in a better understanding of molecular mechanisms that allow establishment and maintenance of HBV and HCV infections, in the hope of developing novel antiviral strategies (either directly targeting the virus or through modulation of immune functions modulation). Our global purpose is to contribute to the eradication of hepatic viral infections, the prevention of liver cancer and the regression of its precursor pathologies such as fibrosis and cirrhosis.